CRL Stock: Price, Earnings History and SEC Filings
Charles River Laboratories International, Inc. (CRL) last traded at $359.41, down 4.44% on the latest session and up 21.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $3.02 against an analyst estimate of $2.72, a beat of 11.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CRL earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $3.02 | $2.72 | +11.03% |
| Mar 2026 | May 7, 2026 | $2.06 | $1.96 | +5.10% |
| Dec 2025 | Feb 18, 2026 | $2.39 | $2.33 | +2.58% |
| Sep 2025 | Nov 5, 2025 | $2.43 | $2.32 | +4.74% |
CRL beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How CRL reacts to earnings
Across its last 8 earnings releases, CRL moved 6.7% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | +11.36% |
| 2026-05-07 | Before open | -0.03% |
| 2026-02-18 | Before open | -0.33% |
| 2026-01-13 | Before open | +0.08% |
| 2025-11-05 | Before open | -5.71% |
| 2025-08-06 | Before open | -10.25% |
| 2025-05-07 | Before open | +18.68% |
| 2025-02-19 | Before open | +6.87% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CRL financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $4.0B | -$144M | – | -3.6% | $-2.91 |
| 2024 | $4.0B | $22M | – | 0.5% | $0.20 |
| 2023 | $4.1B | $475M | – | 11.5% | $9.22 |
| 2022 | $4.0B | $486M | – | 12.2% | $9.48 |
| 2021 | $3.5B | $391M | – | 11.0% | $7.60 |
| 2020 | $2.9B | $364M | – | 12.5% | $7.20 |
| 2019 | $2.6B | $252M | – | 9.6% | $5.07 |
| 2018 | $2.3B | $226M | – | 10.0% | $4.62 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CRL
- 8-K · Sep 24, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · May 11, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Mar 31, 2026
- 8-K · Feb 25, 2026Regulation FD disclosure
- 8-K · Feb 18, 2026Officer or director change, Financial statements and exhibits
- 10-K · Feb 18, 2026
Insider filing activity
CRL insiders filed 15 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CRL news
- Charles River (CRL) Stock Could Be 27% Overvalued As Preclinical FDA Collaboration StartsOct 30, 2026 · finance.yahoo.com
- Charles River Laboratories (CRL) Expands Virtual Control Group Use In Toxicology StudiesOct 30, 2026 · finance.yahoo.com
- Labcorp Holdings (LH) Expands HPV Testing While Teaming With Regulators On Drug SafetyOct 29, 2026 · finance.yahoo.com
- Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Charles River (CRL) Rises on Strong Earnings and Improving Biopharma DemandOct 28, 2026 · finance.yahoo.com
- In Vivo Contract Research Organization (CRO) - Global Strategic Business Report (2026-2032) Featuring Strategic Intelligence on Charles River, ICON, Parexel and WuXi AppTecOct 28, 2026 · finance.yahoo.com
- Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?Oct 28, 2026 · finance.yahoo.com
- Charles River Laboratories International (CRL) Contributed to Madison Small Cap Fund’s Healthcare OutperformanceOct 27, 2026 · finance.yahoo.com
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (CRL) is a US-listed public company on NYSE. The SEC classifies its business as Services-commercial Physical & Biological Research. Its fiscal year ends in December.